Collaborating to heal addiction and mental health in primary care (CHAMP): A protocol for a hybrid type 2a trial
- PMID: 39322115
- PMCID: PMC11584174
- DOI: 10.1016/j.cct.2024.107700
Collaborating to heal addiction and mental health in primary care (CHAMP): A protocol for a hybrid type 2a trial
Abstract
Background: The gold-standard treatment for opioid use disorder (OUD) is medication for OUD (MOUD). However, less than a quarter of people with OUD initiate MOUD. Expanding the Collaborative Care Model (CoCM) to include primary care patients with OUD could improve access to and initiation of MOUD. This paper presents the methods and baseline sample characteristics of a Hybrid Type 2a trial comparing the effectiveness of CoCM for OUD and co-occurring mental health symptoms (MHS) to CoCM for MHS only.
Method: 42 primary care clinics were cluster randomized and 254 primary care patients with OUD and elevated MHS were enrolled. Recruitment was terminated early by the Data and Safety Monitoring Board for futility. Participants completed research assessments at baseline, 3 months, and 6 months. The multiple primary outcomes were past-month number of days of nonmedical opioid use and SF12 Mental Health Component Summary (MCS) scores.
Results: MCS scores were over a standard deviation below the national mean (M = 34.5). Nearly half (47.6 %) of participants had previously overdosed in their lifetimes. Three quarters (76.0 %) were already being prescribed MOUD at baseline, only 30.4 % reported non-medical use of opioids, and only 33.9 % reported being bothered by opioid cravings.
Conclusion: The unexpectedly high proportion of enrollees already prescribed MOUD at baseline indicates that most patients were in the maintenance rather than acute phase of treatment. Challenges identifying and enrolling patients in the acute phase of OUD treatment implies that intervention effectiveness will depend on its success preventing the discontinuation of MOUD rather than initiating MOUD.
Keywords: Collaborative care; Hybrid trial; Opioid use disorder; Primary care.
Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors do not have any personal, professional, or financial conflicts of interest to disclose for this work. Dr. Saxon has received travel support from Alkermes, Inc., consulting fees from Indivior, Inc., and royalties from UpToDate, Inc. Dr. Ratzliff receives royalties from Wiley for her book on integrated care.
Figures
References
-
- SAMSHA. Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health In: Center for Behavioral Health Statistics and Quality SAaMHSA, ed. Rockville, MD2022.
-
- National_Center_for_Health_Statistics CfDCaP. Provisional drug overdose death counts. October 1, 2023; https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm Accessed Oct 17,2023, 2023.
-
- Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England: ). 2019;393(10173):778–790. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
